<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We report a case of renal <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> in a 40-year-old woman with APS </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:hpo ids='HP_0000112'>nephropathy</z:hpo> was isolated without signs of disseminated <z:e sem="disease" ids="C0034155" disease_type="Disease or Syndrome" abbrv="">thrombotic microangiopathy</z:e> or progressive systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Similarities with sclerodermatous kidney and an increase in plasma renin activity led us to initiate treatment with aspirin and <z:chebi fb="0" ids="3380">captopril</z:chebi>, with excellent control of the renal syndrome </plain></SENT>
<SENT sid="4" pm="."><plain>We believe this therapeutic regimen may be an effective means of treating the renal <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> of APS </plain></SENT>
</text></document>